Testosterone Lawsuit News: European Regulators Issue New Testosterone Heart Warning, Bernstein Liebhard LLP Reports

Share Article

The new warning cites a possible association between testosterone medications and serious heart problems, complications which have also been alleged in hundreds of testosterone lawsuits currently pending in U.S. courts.

Free Case Review
Our Firm has heard from numerous men who suffered serious heart problems allegedly related to the use of low testosterone therapy. We are closely monitoring regulatory action in regards to these medications, both in the U.S. and abroad.

As testosterone lawsuits (http://www.testosteronelawsuithub.com/) continue to be filed in U.S. courts against the manufacturers of AndroGel and similar drugs, Bernstein Liebhard LLP notes that European regulators have issued new guidance on the use of low testosterone therapy that seeks to address their potential cardiovascular side effects. According to a statement issued on November 21st, the European Medicines Agency (EMA) now advises the use of these medications be limited to men who suffer from testosterone deficiency (hypogonadism) that has been medically confirmed via signs, symptoms and laboratory tests. The agency also ordered that the labeling for low testosterone therapy treatments be updated with new warnings about their potential heart risks, and recommended that patients who already suffer from heart, liver, or kidney problems be taken off testosterone drugs immediately.*

“Our Firm has heard from numerous men who suffered serious heart problems allegedly related to the use of low testosterone therapy. We are closely monitoring regulatory action in regards to these medications, both in the U.S. and abroad,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating legal claims on behalf of men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism and other life-threatening heart problems due to their use of prescription testosterone medications.

Testosterone Litigation
Testosterone medications, such as AndroGel, Axiron, and Testim have also faced scrutiny from U.S. regulators. In January, the Food & Drug Administration (FDA) announced it was investigating the cardiovascular risks associated with low testosterone therapy. Since then, a panel of FDA advisors recommended that the drugs’ labels be revised to make clear they have not been shown to lessen low libido, fatigue, muscle loss and other age-related symptoms. They also recommended that the manufacturers of testosterone replacement therapies be required to conduct studies of their cardiovascular side effects.**

Court documents indicate that nearly 260 testosterone lawsuits are now pending in a federal multidistrict litigation underway in U.S. District Court, Northern District of Illinois, all of which allege the medications are associated with an increased risk of heart attack, stroke and other life-threatening cardiovascular events. Among other things, the complaints claim that the manufacturers of low testosterone therapies failed to warn doctors and patients about their potential risks, and concealed those dangers from the public. The lawsuits further allege that sales of testosterone replacement products were driven by deceptive marketing tactics that induced many healthy men to use the drugs in the absence of a true medical need. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)

Men who allegedly suffered serious heart side effects due to their use of prescription testosterone therapies may be entitled to compensation from the manufacturers of these medications. To learn more about filing a testosterone treatment lawsuit, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.

*ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Testosterone-containing_medicines/human_referral_prac_000037.jsp&mid=WC0b01ac05805c516f, EMA, November 21, 2014
**reuters.com/article/2014/09/17/us-usa-health-testosterone-idUSKBN0HC2C320140917, Reuters, September 18, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.testosteronelawsuithub.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website